144 related articles for article (PubMed ID: 17914325)
1. Pharmacogenetics in modern psychiatry.
Mihaljević-Peles A; Bozina N; Sagud M
Psychiatr Danub; 2007 Sep; 19(3):231-3. PubMed ID: 17914325
[TBL] [Abstract][Full Text] [Related]
2. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder.
Kato M; Fukuda T; Serretti A; Wakeno M; Okugawa G; Ikenaga Y; Hosoi Y; Takekita Y; Mandelli L; Azuma J; Kinoshita T
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):398-404. PubMed ID: 17913323
[TBL] [Abstract][Full Text] [Related]
3. Could pharmacogenetics play a role as predictor in treatment of depressive disorders?
Lee MS
World J Biol Psychiatry; 2007; 8(1):2-3. PubMed ID: 17366343
[No Abstract] [Full Text] [Related]
4. Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder.
Bozina N; Peles AM; Sagud M; Bilusic H; Jakovljevic M
World J Biol Psychiatry; 2008; 9(3):190-7. PubMed ID: 17853254
[TBL] [Abstract][Full Text] [Related]
5. Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder.
Simoons M; Mulder H; Appeldoorn JTY; Risselada AJ; Schene AH; van Schaik RHN; van Roon EN; Ruhé EG
Psychiatr Genet; 2020 Feb; 30(1):19-29. PubMed ID: 31634334
[TBL] [Abstract][Full Text] [Related]
6. Pharamacogenetics and antidepressant treatment in integrative psychiatry perspective.
Mihaljević-Peles A; Sagud M; Bozina N; Zivković M
Psychiatr Danub; 2008 Sep; 20(3):399-401. PubMed ID: 18827770
[TBL] [Abstract][Full Text] [Related]
7. Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder.
Ruhé HG; Ooteman W; Booij J; Michel MC; Moeton M; Baas F; Schene AH
Pharmacogenet Genomics; 2009 Jan; 19(1):67-76. PubMed ID: 18987562
[TBL] [Abstract][Full Text] [Related]
8. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.
Murphy GM; Hollander SB; Rodrigues HE; Kremer C; Schatzberg AF
Arch Gen Psychiatry; 2004 Nov; 61(11):1163-9. PubMed ID: 15520364
[TBL] [Abstract][Full Text] [Related]
9. The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder.
Tomita T; Yasui-Furukori N; Nakagami T; Tsuchimine S; Ishioka M; Kaneda A; Sugawara N; Kaneko S
PLoS One; 2014; 9(5):e98099. PubMed ID: 24858363
[TBL] [Abstract][Full Text] [Related]
10. Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy.
Stevenson JM
Pharmacogenomics; 2018 Feb; 19(3):167-170. PubMed ID: 29325499
[No Abstract] [Full Text] [Related]
11. Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder.
Ball WA; Snavely DB; Hargreaves RJ; Szegedi A; Lines C; Reines SA
Hum Psychopharmacol; 2014 Nov; 29(6):568-77. PubMed ID: 25330122
[TBL] [Abstract][Full Text] [Related]
12. Is 5-HTTLPR linked to the response of selective serotonin reuptake inhibitors in MDD?
Illi A; Poutanen O; Setälä-Soikkeli E; Kampman O; Viikki M; Huhtala H; Mononen N; Haraldsson S; Koivisto PA; Leinonen E; Lehtimäki T
Eur Arch Psychiatry Clin Neurosci; 2011 Mar; 261(2):95-102. PubMed ID: 20640435
[TBL] [Abstract][Full Text] [Related]
13. Genetic screening for SSRI drug response among those with major depression: great promise and unseen perils.
Rasmussen-Torvik LJ; McAlpine DD
Depress Anxiety; 2007; 24(5):350-7. PubMed ID: 17096399
[TBL] [Abstract][Full Text] [Related]
14. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.
Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK
JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients.
Kato M; Wakeno M; Okugawa G; Fukuda T; Takekita Y; Hosoi Y; Azuma J; Kinoshita T; Serretti A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):1041-4. PubMed ID: 18325652
[TBL] [Abstract][Full Text] [Related]
16. ABCB1 polymorphism predicts escitalopram dose needed for remission in major depression.
Singh AB; Bousman CA; Ng CH; Byron K; Berk M
Transl Psychiatry; 2012 Nov; 2(11):e198. PubMed ID: 23188198
[TBL] [Abstract][Full Text] [Related]
17. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.
Hu XZ; Rush AJ; Charney D; Wilson AF; Sorant AJ; Papanicolaou GJ; Fava M; Trivedi MH; Wisniewski SR; Laje G; Paddock S; McMahon FJ; Manji H; Lipsky RH
Arch Gen Psychiatry; 2007 Jul; 64(7):783-92. PubMed ID: 17606812
[TBL] [Abstract][Full Text] [Related]
18. Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors.
Smits K; Smits L; Peeters F; Schouten J; Janssen R; Smeets H; van Os J; Prins M
Int Clin Psychopharmacol; 2007 May; 22(3):137-43. PubMed ID: 17414739
[TBL] [Abstract][Full Text] [Related]
19. Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence.
Zhu J; Klein-Fedyshin M; Stevenson JM
Pharmacotherapy; 2017 Sep; 37(9):1089-1104. PubMed ID: 28654193
[TBL] [Abstract][Full Text] [Related]
20. Norepinephrine and serotonin transporter genes: impact on treatment response in depression.
Baffa A; Hohoff C; Baune BT; Müller-Tidow C; Tidow N; Freitag C; Zwanzger P; Deckert J; Arolt V; Domschke K
Neuropsychobiology; 2010; 62(2):121-31. PubMed ID: 20588071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
